Lyell Immunopharma (LYEL) analyst forecast and price target
Analyst forecast
Consensus of 8 analyst ratings
Based on 5 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Stifel | Initiated Coverage | Buy | $36.00 | Aug 6, 2026 |
| B. Riley Securities | Initiated Coverage | Buy | $44.00 | Jul 22, 2026 |
| Needham | Maintained | Buy | $44.00 | Jun 15, 2026 |
| Citizens | Maintained | Market Outperform | $34.00 | Jun 15, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $45.00 | Jun 9, 2026 |
| Needham | Maintained | Buy | $44.00 | Jun 8, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $45.00 | Jun 3, 2026 |
| Needham | Maintained | Buy | $44.00 | May 7, 2026 |
| Needham | Initiated Coverage | Buy | $44.00 | Apr 10, 2026 |
| Citizens | Initiated Coverage | Market Outperform | $34.00 | Mar 9, 2026 |
| HC Wainwright & Co. | Upgraded | Neutral → Buy | $45.00 from $20.00 | Dec 9, 2025 |
| HC Wainwright & Co. | Maintained | Neutral | $20.00 from $10.00 | Nov 24, 2025 |
| LUCID CAPITAL MARKETS | Initiated Coverage | Buy | $20.00 | Sep 26, 2025 |
| HC Wainwright & Co. | Maintained | Neutral | $10.00 from $1.00 | Jun 24, 2025 |
| HC Wainwright & Co. | Maintained | Neutral | $1.00 | Apr 16, 2025 |
| HC Wainwright & Co. | Maintained | Neutral | $1.00 | Mar 13, 2025 |
| HC Wainwright & Co. | Maintained | Neutral | $1.00 | Nov 12, 2024 |
| B of A Securities | Downgraded | Buy → Underperform | $1.00 from $6.00 | Oct 30, 2024 |
| HC Wainwright & Co. | Maintained | Neutral | $1.00 | Oct 28, 2024 |
| HC Wainwright & Co. | Maintained | Neutral | $1.00 | Aug 19, 2024 |
Frequently asked questions
What is the price target for LYEL stock?
The average 12-month analyst price target for Lyell Immunopharma (LYEL) is $40.60, with a high estimate of $45.00 and a low of $34.00, across 5 analysts.
Is LYEL a buy, sell, or hold?
Analysts covering Lyell Immunopharma currently average a Buy rating: 7 buy, 0 hold and 1 sell, from 8 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for LYEL?
The average price target of $40.60 implies 185.31% upside from the last price of $14.23.
What is the latest analyst rating on LYEL?
On Aug 6, 2026, Stifel initiated coverage of Lyell Immunopharma at Buy with a price target of $36.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.